| Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. | Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.
Mazzu YZ, Liao YR, Nandakumar S, Jehane LE, Koche RP, Rajanala SH, Li R, Zhao H, Gerke TA, Chakraborty G, Lee GM, Nanjangud GJ, Gopalan A, Chen Y, Kantoff PW., Free PMC Article | 07/28/2024 |
| Regulatory mechanisms and therapeutic potential of JAB1 in neurological development and disorders. | Regulatory mechanisms and therapeutic potential of JAB1 in neurological development and disorders.
Yang Y, Song R, Gao Y, Yu H, Wang S., Free PMC Article | 07/5/2023 |
| METTL3 upregulates COPS5 expression in osteosarcoma in an m(6)A-related manner to promote osteosarcoma progression. | METTL3 upregulates COPS5 expression in osteosarcoma in an m(6)A-related manner to promote osteosarcoma progression.
Zhang C, Wan J, Liu Q, Long F, Wen Z, Liu Y. | 10/15/2022 |
| Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer's Disease. | Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer's Disease.
Martínez-Iglesias O, Naidoo V, Carrera I, Cacabelos R., Free PMC Article | 04/2/2022 |
| PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of beta-catenin and PD-L1. | PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
Ma Y, Xia P, Wang Z, Xu J, Zhang L, Jiang Y., Free PMC Article | 02/5/2022 |
| PD_BiBIM: Biclustering-based biomarker identification in ESCC microarray data. | PD_BiBIM: Biclustering-based biomarker identification in ESCC microarray data.
Patowary P, Bhattacharyya DK. | 12/4/2021 |
| Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-kappaB/STAT3 and NF-kappaB/CSN5 signaling pathways. | Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z, Liang M, Shang L, Lai M, Deng X, Su X. | 11/22/2021 |
| CSN5 Promotes Carcinogenesis of Thyroid Carcinoma Cells Through ANGPTL2. | CSN5 Promotes Carcinogenesis of Thyroid Carcinoma Cells Through ANGPTL2.
Xie P, Wang H, Fang J, Du D, Tian Z, Zhen J, Liu Y, Ding Y, Fu B, Liu F, Huang D, Yu J. | 09/11/2021 |
| JAB1 promotes palmitate-induced insulin resistance via ERK pathway in hepatocytes. | JAB1 promotes palmitate-induced insulin resistance via ERK pathway in hepatocytes.
Zhao Y, Ma S, Hu X, Feng M, Xiang R, Li M, Liu C, Lu T, Huang A, Chen J, Wu M, Lu H. | 07/24/2021 |
| Jab1/Cops5: a promising target for cancer diagnosis and therapy. | Jab1/Cops5: a promising target for cancer diagnosis and therapy.
Yuan C, Wang D, Liu G, Pan Y. | 06/26/2021 |
| alpha5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer. | α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
Chen X, Jia Y, Zhang Y, Zhou D, Sun H, Ma X., Free PMC Article | 05/1/2021 |
| Nuclear beta-catenin expression is positively regulated by JAB1 in human colorectal cancer cells. | Nuclear β-catenin expression is positively regulated by JAB1 in human colorectal cancer cells.
Nishimoto A, Takemoto Y, Saito T, Kurazumi H, Tanaka T, Harada E, Shirasawa B, Hamano K. | 03/20/2021 |
| Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinoma. | Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinoma.
Shen Q, Shang B, Jiang B, Wang Y, Wang Z, Chen G., Free PMC Article | 03/13/2021 |
| Contribution of Immunohistochemistry in Revealing S100A7/JAB1 Colocalization in Psoriatic Epidermal Keratinocyte. | Contribution of Immunohistochemistry in Revealing S100A7/JAB1 Colocalization in Psoriatic Epidermal Keratinocyte.
Granata M, Skarmoutsou E, Mazzarino MC, Libra M, D'Amico F. | 02/2/2021 |
| The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo. | The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo.
Samsa WE, Mamidi MK, Bashur LA, Elliott R, Miron A, Chen Y, Lee B, Greenfield EM, Chan R, Danielpour D, Zhou G., Free PMC Article | 11/28/2020 |
| CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein. | CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein.
Huang M, Xiong H, Luo D, Xu B, Liu H. | 11/21/2020 |
| CSN5 inhibition triggers inflammatory signaling and Rho/ROCK-dependent loss of endothelial integrity. | CSN5 inhibition triggers inflammatory signaling and Rho/ROCK-dependent loss of endothelial integrity.
Majolée J, Pronk MCA, Jim KK, van Bezu JSM, van der Sar AM, Hordijk PL, Kovačević I., Free PMC Article | 10/31/2020 |
| High Jab1 expression is associated with psoriasis. | S100A7, Jab1, and p27(kip1) expression in psoriasis and S100A7 CRISPR-activated human keratinocyte cell line.
Granata M, Skarmoutsou E, Gangemi P, Mazzarino MC, D'Amico F. | 07/18/2020 |
| The oncoproteins are all associated with the abovementioned key oncogenic pathways, may play critical roles in the putative oncogenic function of JAB1 in prostate cancer. | JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer.
Danielpour D, Purighalla S, Wang E, Zmina PM, Sarkar A, Zhou G. | 06/27/2020 |
| The oncogenic effects of CSN5 on OS cells were EGFR dependent. | CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis.
Wan Z, Huang S, Mo F, Yao Y, Liu G, Han Z, Chen M, Zhiyun L. | 06/20/2020 |
| Results found JAB1 expression increased in triple-negative breast cancer (TNBC) cells and associated with poor prognosis. Also, JAB1 expression was regulated by miR-17 in TNBC cells. miR-17 suppressed JAB1's oncogenic function, leading to tumor growth inhibition and sensitizing TNBC cells to chemotherapy. | MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S, Oh DY, Leventaki V, Drakos E, Zhang R, Sahin AA, Resetkova E, Edgerton ME, Wu W, Claret FX. | 05/23/2020 |
| CSN5 directly bound FOXM1 and decreased its ubiquitination. | CSN5 promotes the invasion and metastasis of pancreatic cancer by stabilization of FOXM1.
Mao L, Le S, Jin X, Liu G, Chen J, Hu J. | 05/16/2020 |
| Depletion of Jab1 contributes to the sensitivity of breast cancer cell to adriamycin and cisplatin. | Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51.
Liu G, Yu M, Wu B, Guo S, Huang X, Zhou F, Claret FX, Pan Y. | 02/29/2020 |
| Study shows that Cullin-RING Ligase-2 (CRL2) activates CSN5/CSN6 in a neddylation-independent manner. The presence of NEDD8 is required to activate the CSN5 active site. Synergising cryo-electron microscopy with mass spectrometry, study identified sensory regions of the COP9 signalosome that mediate its stepwise activation and provide a framework for understanding the regulatory mechanism of other Cullin family members. | Structural basis of Cullin 2 RING E3 ligase regulation by the COP9 signalosome.
Faull SV, Lau AMC, Martens C, Ahdash Z, Hansen K, Yebenes H, Schmidt C, Beuron F, Cronin NB, Morris EP, Politis A., Free PMC Article | 12/28/2019 |
| Study found that Jab1 expression levels were relatively higher in most of the examined biliary tract cancer (BTC) cell lines. Its silencing induced anti-proliferative and anti-migratory effects and resulted in G1 cell cycle arrest in BTC cell lines. | Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ., Free PMC Article | 12/21/2019 |